{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:15:48Z","timestamp":1791875748467,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,26]],"date-time":"2027-08-26T00:00:00Z","timestamp":1819238400000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.amjmed.2026.04.019","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:11:05Z","timestamp":1776467465000},"page":"1365-1374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of SGLT-2 inhibitors on portal hypertensive complications and mortality in patients with cirrhosis"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6072-0309","authenticated-orcid":false,"given":"Abhinav K.","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don C.","family":"Rockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.amjmed.2026.04.019_bib0001","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","article-title":"Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by Empagliflozin","volume":"4","author":"Juni","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"10.1016\/j.amjmed.2026.04.019_bib0002","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1479164117733626","article-title":"Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis","volume":"15","author":"Gaspari","year":"2018","journal-title":"Diab Vasc Dis Res"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2026.04.019_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-017-9827-9","article-title":"The portal hypertension syndrome: etiology, classification, relevance, and animal models","volume":"12","author":"Bosch","year":"2018","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.amjmed.2026.04.019_bib0004","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.amjmed.2026.04.019_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11894-006-0058-9","article-title":"Pharmacologic therapy for gastrointestinal bleeding due to portal hypertension and esophageal varices","volume":"8","author":"Rockey","year":"2006","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"10.1016\/j.amjmed.2026.04.019_bib0006","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/hep.1840220145","article-title":"The treatment of portal hypertension: a meta-analytic review","volume":"22","author":"D'Amico","year":"1995","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.amjmed.2026.04.019_bib0007","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.amjmed.2026.04.019_bib0008","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus","volume":"6","author":"Arai","year":"2022","journal-title":"Hepatol Commun"},{"issue":"8","key":"10.1016\/j.amjmed.2026.04.019_bib0009","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.amjmed.2026.04.019_bib0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.amjmed.2026.04.019_bib0011","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s11739-025-03902-w","article-title":"The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease","volume":"20","author":"Amin","year":"2025","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1016\/j.amjmed.2026.04.019_bib0012","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/HEP.0000000000000837","article-title":"Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study","volume":"80","author":"Chung","year":"2024","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.amjmed.2026.04.019_bib0013","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/dom.16198","article-title":"Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: sub-analysis of a randomized controlled study","volume":"27","author":"Hirayama","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"16","key":"10.1016\/j.amjmed.2026.04.019_bib0014","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2169\/internalmedicine.4398-19","article-title":"SGLT2 Inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology","volume":"59","author":"Akuta","year":"2020","journal-title":"Intern Med"},{"issue":"5","key":"10.1016\/j.amjmed.2026.04.019_bib0015","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.amjmed.2026.04.019_bib0016","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep4.2005","article-title":"Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: a 5-year follow-up study","volume":"6","author":"Akuta","year":"2022","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.amjmed.2026.04.019_bib0017","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","article-title":"Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"73","author":"Mao","year":"2024","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.amjmed.2026.04.019_bib0018","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.amjmed.2026.04.019_bib0019","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.amjmed.2026.04.019_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18470","article-title":"Sodium-glucose cotransporter 2 inhibitors and serious liver events in patients with cirrhosis","volume":"8","author":"Abu-Hammour","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.amjmed.2026.04.019_bib0021","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.31726","article-title":"Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement","volume":"74","author":"Hagstrom","year":"2021","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.amjmed.2026.04.019_bib0022","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000469","article-title":"Validating new coding algorithms to improve identification of alcohol-associated and nonalcohol-associated cirrhosis hospitalizations in administrative databases","volume":"8","author":"Swain","year":"2024","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.amjmed.2026.04.019_bib0023","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MCG.0000000000001586","article-title":"An AI approach for identifying patients with cirrhosis","volume":"57","author":"Obeid","year":"2023","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.amjmed.2026.04.019_bib0024","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1007\/s10620-020-06388-y","article-title":"Development of an algorithm to identify cases of nonalcoholic steatohepatitis cirrhosis in the electronic health record","volume":"66","author":"Danford","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.amjmed.2026.04.019_bib0025","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000386","article-title":"The future of International Classification of Diseases coding in steatotic liver disease: an expert panel Delphi consensus statement","volume":"8","author":"Hagstrom","year":"2024","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.amjmed.2026.04.019_bib0026","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.cgh.2019.12.017","article-title":"Identifying patients with hepatic encephalopathy using administrative data in the ICD-10 era","volume":"19","author":"Tapper","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.amjmed.2026.04.019_bib0027","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1007\/s10620-023-07876-7","article-title":"Accurate identification of patients with cirrhosis and its complications in the electronic health record","volume":"68","author":"Khalifa","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.amjmed.2026.04.019_bib0028","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/1753-0407.13136","article-title":"SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: a tertiary center cohort study and insights about a potential therapeutic target for portal hypertension","volume":"13","author":"Saffo","year":"2021","journal-title":"J Diabetes"},{"key":"10.1016\/j.amjmed.2026.04.019_bib0029","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.amjmed.2026.04.019_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system","volume":"12","author":"Puglisi","year":"2021","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.amjmed.2026.04.019_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030629","article-title":"Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the Renin-Angiotensin system","volume":"20","author":"Ansary","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.amjmed.2026.04.019_bib0032","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.amjmed.2026.04.019_bib0033","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.amjmed.2026.04.019_bib0034","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"10.1016\/j.amjmed.2026.04.019_bib0035","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s12325-016-0457-8","article-title":"Factors affecting Canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus","volume":"34","author":"Tanaka","year":"2017","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.amjmed.2026.04.019_bib0036","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40360-017-0125-x","article-title":"Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes","volume":"18","author":"Kawasoe","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.amjmed.2026.04.019_bib0037","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","article-title":"Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies","volume":"1","author":"Akuta","year":"2017","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.amjmed.2026.04.019_bib0038","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.amjmed.2026.04.019_bib0039","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211000243","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data","volume":"12","author":"Arai","year":"2021","journal-title":"Ther Adv Endocrinol Metab"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326002949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326002949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:09:16Z","timestamp":1787778556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326002949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0002934326002949"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.04.019","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of SGLT-2 inhibitors on portal hypertensive complications and mortality in patients with cirrhosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}